Ignite Creation Date:
2025-12-25 @ 2:44 AM
Ignite Modification Date:
2025-12-30 @ 10:15 PM
Study NCT ID:
NCT07081633
Status:
RECRUITING
Last Update Posted:
2025-10-29
First Post:
2025-06-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-08-05
Start Date Type:
ACTUAL
Primary Completion Date:
2026-11-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-06-23
First Submit QC Date:
None
Study First Post Date:
2025-07-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-28
Last Update Post Date:
2025-10-29
Last Update Post Date Type:
ESTIMATED